Literature DB >> 23135940

Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens.

P Rocco LaSala1, Tariq Ekhmimi, A Kate Hill, Imran Farooqi, Peter L Perrotta.   

Abstract

Quantitative fecal lactoferrin was measured in 112 patients tested for toxigenic Clostridium difficile using glutamate dehydrogenase (GDH) and toxin immunoassays combined with tcdB PCR. Lactoferrin levels were higher in the GDH-positive/toxin-positive group (79 μg/ml) than in the GDH-positive/toxin-negative/PCR-positive (21 μg/ml) and the GDH-negative groups (13 μg/ml). Differences in fecal lactoferrin levels suggest variable presence or severity of C. difficile infection among toxin-positive and toxin-negative patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135940      PMCID: PMC3536223          DOI: 10.1128/JCM.02735-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system.

Authors:  Alex B Ryder; Ying Huang; Haijing Li; Min Zheng; Xiaobo Wang; Charles W Stratton; Xiao Xu; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection?

Authors:  Mark H Wilcox; Tim Planche; Ferric C Fang; Peter Gilligan
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

3.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

Authors:  T S Steiner; C A Flores; T T Pizarro; R L Guerrant
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

4.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

5.  Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.

Authors:  Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

6.  Outcomes in patients tested for Clostridium difficile toxins.

Authors:  Christopher R Polage; David L Chin; Jhansi L Leslie; Jevon Tang; Stuart H Cohen; Jay V Solnick
Journal:  Diagn Microbiol Infect Dis       Date:  2012-09-23       Impact factor: 2.803

7.  Comparison of fecal lactoferrin latex agglutination assay and methylene blue microscopy for detection of fecal leukocytes in Clostridium difficile-associated disease.

Authors:  W H Yong; A R Mattia; M J Ferraro
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

8.  Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea.

Authors:  Lance R Peterson; Rebecca U Manson; Suzanne M Paule; Donna M Hacek; Ari Robicsek; Richard B Thomson; Karen L Kaul
Journal:  Clin Infect Dis       Date:  2007-09-25       Impact factor: 9.079

9.  Laboratory diagnosis of clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory.

Authors:  M W D Wren; M Sivapalan; R Kinson; N R Shetty
Journal:  Br J Biomed Sci       Date:  2009       Impact factor: 3.829

10.  Clostridium difficile colitis: an efficient clinical approach to diagnosis.

Authors:  Y C Manabe; J M Vinetz; R D Moore; C Merz; P Charache; J G Bartlett
Journal:  Ann Intern Med       Date:  1995-12-01       Impact factor: 25.391

View more
  10 in total

1.  Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.

Authors:  F Barbut; C Gouot; N Lapidus; L Suzon; R Syed-Zaidi; V Lalande; C Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

2.  Quantitative Fecal Lactoferrin as a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients.

Authors:  Laurie R Archbald-Pannone
Journal:  J Geriatr Palliat Care       Date:  2014

Review 3.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.

Authors:  Krishna Rao; Kavitha Santhosh; Jill A Mogle; Peter D R Higgins; Vincent B Young
Journal:  Infect Dis (Lond)       Date:  2016-05-20

5.  Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.

Authors:  J H Boone; L R Archbald-Pannone; K N Wickham; R J Carman; R L Guerrant; C T Franck; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

Review 6.  Antimicrobial proteins in intestine and inflammatory bowel diseases.

Authors:  Jung Mogg Kim
Journal:  Intest Res       Date:  2014-01-28

7.  Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.

Authors:  C H Chilton; G S Crowther; K Śpiewak; M Brindell; G Singh; M H Wilcox; T M Monaghan
Journal:  J Antimicrob Chemother       Date:  2016-01-11       Impact factor: 5.790

8.  Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Authors:  J H Boone; J R DiPersio; M J Tan; S-J Salstrom; K N Wickham; R J Carman; H R Totty; R E Albert; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-18       Impact factor: 3.267

9.  Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Authors:  Andrew Swale; Fabio Miyajima; Paul Roberts; Amanda Hall; Margaret Little; Mike B J Beadsworth; Nick J Beeching; Ruwanthi Kolamunnage-Dona; Chris M Parry; Munir Pirmohamed
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

10.  Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection.

Authors:  Anna Maria Seekatz; Krishna Rao; Kavitha Santhosh; Vincent Bensan Young
Journal:  Genome Med       Date:  2016-04-27       Impact factor: 11.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.